# Michio Painter

> Michio Painter is a seed investor at University of Zurich backing Health Care and Biotechnology. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [University of Zurich](https://shizune.co/investors/profile/university-of-zurich)
- Location: Cambridge, United States
- Total investments: 3
- Last investment: Feb 2024
- Lead investor: 100%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/michio-painter-phd-a3477b58

Michio Painter is a seed investor at University of Zurich in Cambridge focused on Health Care and Biotechnology. Michio Painter is the Head of the Therapy Development Accelerator at University of Zurich.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 67% |
| Biotechnology | 2 | 67% |
| Medical | 1 | 33% |
| Health Diagnostics | 1 | 33% |
| Artificial Intelligence | 1 | 33% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 1 | 33% |
| Convertible Note | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Switzerland | 1 | 33% |
| United States | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| FimmCyte | FimmCyte develops a novel disease modifying treatments for fibro-inflammatory diseases, starting with Endometriosis. | $1.1M | Convertible Note | Feb 28, 2024 |  |
| AOA | AOA Dx is a biotechnology company with a team of entrepreneurs that brings innovative, impactful, and cost-effective medical technologies from research and development into the hands of providers and patients. The company is driven by a mission to bring to market the first accurate early-stage non-invasive ovarian cancer diagnostic test that willimprove clinical practice and help reduce patient mortality. | $2.5M | Seed | Nov 15, 2021 |  |
| AOA | AOA Dx is a biotechnology company with a team of entrepreneurs that brings innovative, impactful, and cost-effective medical technologies from research and development into the hands of providers and patients. The company is driven by a mission to bring to market the first accurate early-stage non-invasive ovarian cancer diagnostic test that willimprove clinical practice and help reduce patient mortality. | $2.5M | Seed | Jun 28, 2021 |  |

3 of 3 investments shown.

## Co-investors
- [Avestria Ventures](https://shizune.co/investors/profile/avestria-ventures) — VC Fund, 2 deals together
- [Beacon Angels](https://shizune.co/investors/profile/beacon-angels) — VC Fund, 2 deals together
- [Kyto Technology and Life Science Inc](https://shizune.co/investors/profile/kyto-technology-and-life-science-inc) — VC Fund, 2 deals together
- [LaunchPad Venture](https://shizune.co/investors/profile/launchpad-venture-group) — VC Fund, 2 deals together
- [Pioneer Fund](https://shizune.co/investors/profile/pioneer-fund) — VC Fund, 2 deals together
- [Sidecar Angels](https://shizune.co/investors/profile/sidecar-angels) — VC Fund, 2 deals together

## About University of Zurich

VC Fund · Zürich, Switzerland

University of Zurich is a higher education institute that offers a wide variety of Master’s, Bachelor’s, and Ph.D. programs. The company also specializes in the fields of clinical medicine, immunology, neuroscience, and structural biology as well as in economics. It also brings benefits to both the private and the public sectors. It makes findingsfrom cutting-edge research available to the public in accessible and engaging lecture series and panel discussions.In addition, the University of Zurich providing a dynamic education based on critical thinking and interdisciplinary exposure. The university is committed to being an internationally significant research university, with graduate, undergraduate, and professional programs of excellent quality.University of Zurich was founded on April 29, 1833, and is headquartered in Zurich, Switzerland.

5 contacts available at University of Zurich.

| Name | Title | Profile |
| --- | --- | --- |
| Michio Painter | Head of the Therapy Development Accelerator | https://shizune.co/investors/profile/michio-painter-15a2 |
| Aron Kirschner | Research Associate | https://shizune.co/investors/profile/aron-kirschner |
| Beth Singler | Assistant Professor in Digital Religion | https://shizune.co/investors/profile/beth-singler |
| Burkhard Becher | Co-Chair | https://shizune.co/investors/profile/burkhard-becher |
| Claudio Tessone | Professor of Blockchain & Distributed Ledger Technologies | https://shizune.co/investors/profile/claudio-tessone |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

## FAQ

### What does Michio Painter invest in?

Michio Painter invests primarily in Health Care, Biotechnology and Medical startups, most often at Seed and Convertible Note stage. Most of the 3 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Michio Painter last invest?

The most recent investment recorded for Michio Painter closed in Feb 2024. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co